In cancers, HGFR is often overexpressed or its activation is dysregulated, driving tumor growth, invasion, and metastasis in cancers including but not limited to non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer, ovarian cancer, pancreatic cancer, and epithelial tissue tumors (Kim et al., 2017; Mori et al., 2021; Yang et al., 2022). Here, MET is linked to renal cell carcinoma.